TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27423422

Group type: EXPERIMENTAL
Intervention: Circulating miRNAs in cases (DF, DH, DC)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Circulating miRNAs in DH or DC cases
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Circulating miRNAs in DC vs. DF cases
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Circulating miRNAs in DC vs. DH cases
Number of subjects: 45
Study: 26125735

Group type: EXPERIMENTAL
Intervention: 3D‐CRT + docetaxel (36 mg/m(2) once weekly for 6 weeks) + adjuvant chemotherapy
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 3D‐CRT + docetaxel + adjuvant chemotherapy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (3D‐CRT + adjuvant chemotherapy)
Number of subjects: 60
Study: 24047455

Group type: EXPERIMENTAL
Intervention: Bracing (at least 18 hours per day)
Number of subjects: 242

Group type: COMPARATOR
Intervention: Observation (control group)
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Bracing (randomly assigned)
Number of subjects: 242

Group type: COMPARATOR
Intervention: Observation (randomly assigned, control group)
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Bracing (hours of wear)
Number of subjects: 242
Study: 20934206

Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) for 3 years
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) for 4 years
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) for 5 years
Number of subjects: 78

Group type: COMPARATOR
Intervention: Control group (drug therapy alone)
Number of subjects: 78
Study: 18081812

Group type: EXPERIMENTAL
Intervention: ProTaper
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Mtwo
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: R‐Endo
Number of subjects: 60

Group type: COMPARATOR
Intervention: Hedström files
Number of subjects: 60
Study: 16782921

Group type: EXPERIMENTAL
Intervention: Docetaxel and estramustine (DE)
Number of subjects: 674

Group type: COMPARATOR
Intervention: Mitoxantrone and prednisone (MP)
Number of subjects: 674
Study: 12677456

Group type: EXPERIMENTAL
Intervention: Electrical Stimulation Therapy (EST)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Biofeedback Therapy (BFT)
Number of subjects: 22
Study: 10988013

Group type: EXPERIMENTAL
Intervention: Tissue plasminogen activator antigen
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Leucocyte elastase
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Whole blood viscosity
Number of subjects: 207
Study: 9402662

Group type: EXPERIMENTAL
Intervention: Current therapeutic strategies for tachyarrhythmias following CABG
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diagnostic tools for postoperative arrhythmias
Number of subjects: 0
Study: 1416271

Group type: EXPERIMENTAL
Intervention: Combined spinal-epidural anesthesia (CSEA)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Spinal anesthesia
Number of subjects: 63
Study: 3161213

Group type: EXPERIMENTAL
Intervention: Org 10172 (800 and 3200 anti‐Xa units)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Heparin (5000 IU)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Org 10172 (34.4 anti‐Xa units/kg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Heparin (34.4 anti‐Xa units/kg)
Number of subjects: 12
Study: 30904428

Group type: EXPERIMENTAL
Intervention: Grouper iridovirus (GIV) challenge; LPS and poly (I:C) challenges; specific genes EcSYCA102, EcSYCA103, EcSYCA116, and EcSYCA118 were highly induced in the spleen after challenge.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: LPS and poly (I:C) challenges; specific genes EcSYCA102, EcSYCA103, EcSYCA116, and EcSYCA118 were upregulated.
Number of subjects: 0
Study: 29417366

Group type: EXPERIMENTAL
Intervention: BFHI steps 1-9
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BFHI steps 1-10
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 0
Study: 26350474

Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP) treatment for 12 weeks
Number of subjects: 80

Group type: COMPARATOR
Intervention: Conservative treatment (CT) for 12 weeks
Number of subjects: 80
Study: 24836438

Group type: EXPERIMENTAL
Intervention: Rapid PCR‐based screening test for MRSA
Number of subjects: 2500

Group type: COMPARATOR
Intervention: Control screening test by enrichment culture using chromogenic agar
Number of subjects: 2500
Study: 22186969

Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIC)
Number of subjects: 1610

Group type: COMPARATOR
Intervention: Sham RIC
Number of subjects: 1610

Group type: EXPERIMENTAL
Intervention: RIC
Number of subjects: 1610
Study: 20670728

Group type: EXPERIMENTAL
Intervention: Venous compression stockings or compression bandages
Number of subjects: 620

Group type: COMPARATOR
Intervention: Control group (no venous compression)
Number of subjects: 620
Study: 19093288

Group type: EXPERIMENTAL
Intervention: Laser light (dual wavelength of 650+/‐20 nm and 915+/‐10 nm) and massage
Number of subjects: 102

Group type: COMPARATOR
Intervention: Massage alone (control)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Laser light and massage
Number of subjects: 102
Study: 15655382

Group type: EXPERIMENTAL
Intervention: lisinopril 20 mg
Number of subjects: 32

Group type: COMPARATOR
Intervention: telmisartan 80 mg
Number of subjects: 32
Study: 11912269

Group type: EXPERIMENTAL
Intervention: FTY720 (0.25 to 3.5 mg)
Number of subjects: 20
Study: 10069195

Group type: EXPERIMENTAL
Intervention: MMF
Number of subjects: 40
Study: 8819181

Group type: EXPERIMENTAL
Intervention: Salmeterol (50 micrograms)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Salbutamol (200 micrograms)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (40 micrograms)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 2105115

Group type: EXPERIMENTAL
Intervention: Cefotaxime 1 g intravenously plus metronidazole 500 mg intravenously preoperatively (Group 1)
Number of subjects: 943

Group type: COMPARATOR
Intervention: Cefuroxime 1.5 g intravenously plus metronidazole 500 mg intravenously preoperatively, followed by cefuroxime 750 mg intravenously plus metronidazole 500 mg intravenously eight hours and 16 hours postoperatively (Group 2)
Number of subjects: 943

Group type: EXPERIMENTAL
Intervention: Cefotaxime plus metronidazole (Group 1)
Number of subjects: 943

Group type: COMPARATOR
Intervention: Cefuroxime plus metronidazole (Group 2)
Number of subjects: 943

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 943
Study: 6446445

Group type: EXPERIMENTAL
Intervention: Mefenamic acid (1500 mg)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Aspirin (3600 mg)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Phenylbutazone (300 mg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Dextropropoxyphene plus paracetamol (260 mg plus 2600 mg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Paracetamol (4000 mg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Indomethacin (150 mg)
Number of subjects: 60
Study: 30193565

Group type: EXPERIMENTAL
Intervention: Short message systems in addition to face to face education
Number of subjects: 100

Group type: COMPARATOR
Intervention: Face to face education
Number of subjects: 100
Study: 31837648

Group type: EXPERIMENTAL
Intervention: tDCS + Nintendo Switch game
Number of subjects: 30

Group type: COMPARATOR
Intervention: sham tDCS
Number of subjects: 30

Group type: COMPARATOR
Intervention: tDCS only (group 3)
Number of subjects: 30
Study: 27808418

Group type: EXPERIMENTAL
Intervention: Lamotrigine (300 mg)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Levetiracetam (3,000 mg)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 26329661

Group type: EXPERIMENTAL
Intervention: Ketorolac (group K)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Tramadol (group T)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Both groups (K and T)
Number of subjects: 200
Study: 23846175

Group type: EXPERIMENTAL
Intervention: Routine postprocedural chest X‐ray (group 1)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Chest X‐ray only when clinically indicated (group 2)
Number of subjects: 100
Study: 21742103

Group type: EXPERIMENTAL
Intervention: Ticagrelor (T)
Number of subjects: 209

Group type: COMPARATOR
Intervention: Clopidogrel (C)
Number of subjects: 209
Study: 19831165

Group type: EXPERIMENTAL
Intervention: 8.0% arginine toothpaste
Number of subjects: 125

Group type: COMPARATOR
Intervention: Benchmark desensitizing toothpaste
Number of subjects: 125

Group type: COMPARATOR
Intervention: Control toothpaste
Number of subjects: 125
Study: 16613932

Group type: EXPERIMENTAL
Intervention: Ensite NavX
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Carto
Number of subjects: 145

Group type: COMPARATOR
Intervention: Conventional mapping
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: NavX
Number of subjects: 145
Study: 15105061

Group type: EXPERIMENTAL
Intervention: NuvaRing (15 microg ethinylestradiol and 120 microg etonogestrel daily)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Combined oral contraceptive (30 microg ethinylestradiol and 150 microg levonorgestrel)
Number of subjects: 83
Study: 11277450

Group type: EXPERIMENTAL
Intervention: Selective rehearsal and cognitive inhibition in children and adults
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cued recall and recognition tests
Number of subjects: 0
Study: 9594355

Group type: EXPERIMENTAL
Intervention: Glyconutritional supplement (saccharides) for six weeks
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Phytonutritional supplement (added after three weeks)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Methylphenidate (prescribed doses maintained or reduced by half)
Number of subjects: 17
Study: 8964329

Group type: EXPERIMENTAL
Intervention: Intravenous methylprednisolone 500 mg Q8 hours for 10 doses followed by oral prednisone for two weeks and tapering doses thereafter
Number of subjects: 16

Group type: COMPARATOR
Intervention: Oral prednisone one mg per kilogram of body weight for two weeks followed by tapering doses
Number of subjects: 16
Study: 2687306

Group type: EXPERIMENTAL
Intervention: Standardized night waking programme involving organized bedtime routines, procedures for settling the child, and handling of crying, calling out, and getting out of bed.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Written information only
Number of subjects: 0

Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 0
Study: 4140005

Group type: EXPERIMENTAL
Intervention: Intranasal beclomethasone dipropionate 200 mug daily
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 31785587

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (OXT; 6 IU, 12 IU, 24 IU)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (OXT)
Number of subjects: 90
Study: 30699178

Group type: EXPERIMENTAL
Intervention: Vacc‐4x booster immunizations (1.2mg) with GM‐CSF (60μg) as a local adjuvant
Number of subjects: 33
Study: 28679021

Group type: EXPERIMENTAL
Intervention: Intravenous administration of oxytocin (10 IU)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Vaginal administration of oxytocin (100 or 400 IU)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Vaginal administration of oxytocin
Number of subjects: 33
Study: 26355232

Group type: EXPERIMENTAL
Intervention: Aflibercept in combination with mFOLFOX6
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 96
Study: 23002282

Group type: EXPERIMENTAL
Intervention: Chemotherapy with pertuzumab (arm A, n=74)
Number of subjects: 149

Group type: COMPARATOR
Intervention: Chemotherapy alone (arm B, n=75)
Number of subjects: 149
Study: 22099466

Group type: EXPERIMENTAL
Intervention: BOLD activity in the VTA
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BOLD activity in ventral striatum (VS)
Number of subjects: 0
Study: 19565733

Group type: EXPERIMENTAL
Intervention: Warm needle moxibustion
Number of subjects: 125

Group type: COMPARATOR
Intervention: Acupuncture
Number of subjects: 125

Group type: COMPARATOR
Intervention: Western medicine (Prostat Tablets)
Number of subjects: 125
Study: 17380850

Group type: EXPERIMENTAL
Intervention: Candesartan 8 mg
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Amlodipine 5 mg
Number of subjects: 49
Study: 15382805

Group type: EXPERIMENTAL
Intervention: ICEX sockets
Number of subjects: 27

Group type: COMPARATOR
Intervention: PTB sockets
Number of subjects: 27
Study: 11421877

Group type: EXPERIMENTAL
Intervention: RBC 400 mg b.d. plus amoxicillin 1 g b.d. and tinidazole 500 mg b.d. (RAT group)
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: RBC 400 mg b.d. plus amoxicillin 1 g b.d. and clarythromycin 500 mg b.d. (RAC group)
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: RBC 400 mg b.d. plus clarythromycin 500 mg b.d. and tinidazole 500 mg b.d. (RCT group)
Number of subjects: 285

Group type: COMPARATOR
Intervention: Maastricht triple therapy
Number of subjects: 285
Study: 9431863

Group type: EXPERIMENTAL
Intervention: Dobutamine (1 micromol/l, 15 min) after hypoxia-reoxygenation
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Felodipine (0.1 micromol/l, n=5) pretreatment (15 min before hypoxia)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: High stimulation rate (400 ms CL) during hypoxia
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Low stimulation rate (1600 ms CL) during hypoxia
Number of subjects: 28

Group type: COMPARATOR
Intervention: Time-related controls (Tyrode's solution for 225 min at cycle length (CL) 1600 ms and no dobutamine)
Number of subjects: 28
Study: 8480740

Group type: EXPERIMENTAL
Intervention: Aspartame (15 mg/kg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Skim milk (equimolar phenylalanine to aspartame)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 3613408

Group type: EXPERIMENTAL
Intervention: Low protein diet
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: High protein diet
Number of subjects: 13
Study: 31599994

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 19
Study: 28483745

Group type: EXPERIMENTAL
Intervention: Mobile app for pelvic floor muscle training (PFMT), prescribed 3 times daily for 3 months.
Number of subjects: 123

Group type: COMPARATOR
Intervention: No treatment (control group).
Number of subjects: 123
Study: 26250359

Group type: EXPERIMENTAL
Intervention: Irbesartan
Number of subjects: 4113

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4113
Study: 23430759

Group type: EXPERIMENTAL
Intervention: Physical exercise
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of genotypes associated with an anti-inflammatory profile
Number of subjects: 0
Study: 21610263

Group type: EXPERIMENTAL
Intervention: Double-bundle technique (DB group)
Number of subjects: 153

Group type: COMPARATOR
Intervention: Single-bundle technique (SB group)
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 153
Study: 18094222

Group type: EXPERIMENTAL
Intervention: High-dose ATRA (2 mg/kg/day)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: 13-cRA (1 mg/kg/day)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Low-dose ATRA (1 mg/kg/day)
Number of subjects: 116
Study: 17178958

Group type: EXPERIMENTAL
Intervention: 5% Povidone-iodine (PVI)
Number of subjects: 517

Group type: COMPARATOR
Intervention: 0.3% Sodium hypochlorite
Number of subjects: 517
Study: 12849825

Group type: EXPERIMENTAL
Intervention: NovaSure endometrial ablation
Number of subjects: 57

Group type: COMPARATOR
Intervention: Cavaterm endometrial ablation
Number of subjects: 57
Study: 10473232

Group type: EXPERIMENTAL
Intervention: Azithromycin 500 mg p.o. od for 7 days
Number of subjects: 77

Group type: COMPARATOR
Intervention: Chloramphenicol 2-3 g p.o. od in four divided doses for 14 days
Number of subjects: 77
Study: 8777096

Group type: EXPERIMENTAL
Intervention: General anaesthesia
Number of subjects: 54

Group type: COMPARATOR
Intervention: Local anaesthesia
Number of subjects: 54
Study: 2066449

Group type: EXPERIMENTAL
Intervention: V6+ (chewing gum containing hydrogen peroxide)
Number of subjects: 12

Group type: COMPARATOR
Intervention: PLAC (V6 placebo gum)
Number of subjects: 12

Group type: COMPARATOR
Intervention: GB (gum base as negative control)
Number of subjects: 12
Study: 7048518

Group type: EXPERIMENTAL
Intervention: Concurrent chemo/hormonotherapy
Number of subjects: 406

Group type: COMPARATOR
Intervention: Hormonal treatment alone with delayed chemotherapy until tumor progression
Number of subjects: 406

Group type: EXPERIMENTAL
Intervention: More aggressive cytotoxic combinations (LMFP, LMP/FVP, LMFP/ADM)
Number of subjects: 406

Group type: COMPARATOR
Intervention: Minimal chemotherapy
Number of subjects: 406
Study: 31719080

Group type: EXPERIMENTAL
Intervention: Pregnant+ app and usual care
Number of subjects: 238

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: Pregnant+ app
Number of subjects: 238
Study: 30220262

Group type: EXPERIMENTAL
Intervention: Ovaprim™ (0.5 ml/kg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Carp pituitary extract (CPE; 2.0 mg/kg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: NaCl solution 0.9% (control group; 0.5 ml/kg)
Number of subjects: 12
Study: 27487909

Group type: EXPERIMENTAL
Intervention: Bilateral TAP block with 20 ml of ropivacaine
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo (isotonic saline)
Number of subjects: 80
Study: 24490628

Group type: EXPERIMENTAL
Intervention: VL + local anesthesia without analgesics
Number of subjects: 884

Group type: COMPARATOR
Intervention: VL + local anesthesia + analgesics
Number of subjects: 884
Study: 21425346

Group type: EXPERIMENTAL
Intervention: Reminiscence group therapy (three sessions per week for 24 weeks)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Weekly individual supportive interviews (control group)
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Both groups (experimental and control)
Number of subjects: 129
Study: 20336063

Group type: EXPERIMENTAL
Intervention: 6-month extended transdermal nicotine therapy
Number of subjects: 471

Group type: COMPARATOR
Intervention: 8-week standard transdermal nicotine therapy
Number of subjects: 471
Study: 16934840

Group type: EXPERIMENTAL
Intervention: Duloxetine 40mg/day
Number of subjects: 1619

Group type: EXPERIMENTAL
Intervention: Duloxetine 60mg/day
Number of subjects: 1619

Group type: EXPERIMENTAL
Intervention: Duloxetine 80mg/day
Number of subjects: 1619

Group type: EXPERIMENTAL
Intervention: Duloxetine 120mg/day
Number of subjects: 1619

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1619
Study: 11315126

Group type: EXPERIMENTAL
Intervention: Crystalloid cardioplegia + L-arginine
Number of subjects: 28

Group type: COMPARATOR
Intervention: Crystalloid cardioplegia
Number of subjects: 28
Study: 9308941

Group type: EXPERIMENTAL
Intervention: Hyperthermia and radiation
Number of subjects: 120
Study: 8340045

Group type: EXPERIMENTAL
Intervention: Naloxone (NLX, 2mg, IV)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo (P, Physiologic saline, 10ml)
Number of subjects: 16
Study: 2947447

Group type: EXPERIMENTAL
Intervention: 20 mg of oral nicorandil
Number of subjects: 11

Group type: COMPARATOR
Intervention: sublingual nitroglycerin
Number of subjects: 11
Study: 29698966

Group type: EXPERIMENTAL
Intervention: Diamine oxidase (DAO) supplementation, 1 capsule b.i.d., 15 min before a meal for 30 days
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Diamine oxidase (DAO) supplementation
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 26364551

Group type: EXPERIMENTAL
Intervention: AZD2014 (50 mg twice daily)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Everolimus (10 mg once daily)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: AZD2014
Number of subjects: 49

Group type: COMPARATOR
Intervention: Everolimus
Number of subjects: 49
Study: 25706861

Group type: EXPERIMENTAL
Intervention: Sleep Restriction (SR) - 6.5 hours in bed
Number of subjects: 31

Group type: COMPARATOR
Intervention: Healthy Sleep (HS) - 10 hours in bed
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Sleep Restriction (SR)
Number of subjects: 31
Study: 23097413

Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma gel (PRPG)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 50
Study: 20942866

Group type: EXPERIMENTAL
Intervention: Concurrent arm (Arm C) - R-CHOP: 6 R treatments (375 mg/m²) 2 days prior to each cycle of CHOP
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Sequential arm (Arm S) - R-CHOP: 6 weekly R treatments (375 mg/m²) following six cycles of CHOP
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Overall for all assessable patients
Number of subjects: 67
Study: 18257603

Group type: EXPERIMENTAL
Intervention: Higher dose of donepezil (15 mg/day for weeks 1-12; 20 mg/day for weeks 13-24)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Standard dose of donepezil (10 mg/day plus placebo 5 mg/day for weeks 1-12; 10 mg/day plus placebo 10 mg/day for weeks 13-24)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Higher dose of donepezil
Number of subjects: 31

Group type: COMPARATOR
Intervention: Standard dose of donepezil
Number of subjects: 31
Study: 16773586

Group type: EXPERIMENTAL
Intervention: Pattern visual evoked potentials (PVEPs)
Number of subjects: 15
Study: 12744985

Group type: EXPERIMENTAL
Intervention: Preventive medicine curriculum (case-based approach)
Number of subjects: 0
Study: 11051124

Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 102

Group type: COMPARATOR
Intervention: Vigabatrin
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Gabapentin (per protocol)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Vigabatrin (per protocol)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Vigabatrin (perimetry results)
Number of subjects: 102
Study: 8791949

Group type: EXPERIMENTAL
Intervention: dirithromycin 500 mg q.d.s. alone
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: dirithromycin 500 mg q.d.s. plus omeprazole 40 mg q.d.s.
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: dirithromycin 500 mg q.d.s. plus metronidazole 500 mg t.d.s.
Number of subjects: 32

Group type: COMPARATOR
Intervention: omeprazole 500 mg q.d.s. plus amoxycillin 20 mg b.d.
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: dirithromycin alone or combined with omeprazole
Number of subjects: 32